MétaCan
Menu
← Back to cohort
Record W4416066694 · doi:10.1681/asn.2025ymhd1j35

Absolute Proteinuria over Time with Nefecon vs. Placebo in Patients with IgAN: Results from the Phase 3 NefIgArd Trial

2025· article· en· W4416066694 on OpenAlexaff
Heather N. Reich, Brad H. Rovin, Richard Lafayette, Russell Jones, Jonathan Barratt

Bibliographic record

VenueJournal of the American Society of Nephrology · 2025
Typearticle
Languageen
FieldMedicine
TopicRenal Diseases and Glomerulopathies
Canadian institutionsUniversity of TorontoUniversity Health Network
Fundersnot available
KeywordsPlaceboProteinuriaPhase (matter)Clinical trialKidney diseaseKidney

Abstract

fetched live from OpenAlex

Background: Proteinuria reduction is a surrogate marker of immunoglobulin A nephropathy (IgAN) treatment effectiveness. Kidney Disease: Improving Global Outcomes (KDIGO) 2021 guidelines consider an absolute reduction to <1 g/day a “reasonable treatment target”. Nefecon is a targeted–release budesonide formulation approved for IgAN. Here, we present absolute proteinuria over time during the Phase 3 NefIgArd trial. Methods: Patients were randomized 1:1 to 16 mg/day nefecon or placebo for 9 months, followed by 15 months off treatment. Absolute urine protein–creatinine ratio (UPCR) changes from baseline over time were derived using results from the mixed effect model repeated measurement on the log-transformed data at months 3, 6, 9, 12, 18, and 24, per the NefIgArd co-primary analysis of UPCR. The percentage change from baseline was then back-transformed using the baseline geometric mean UPCR per treatment group. Results: Absolute geometric mean UPCR decreased by 33.6%, from 1.30 g/gram at baseline to 0.86 g/gram at 9 months with nefecon treatment, with continued reduction to 0.63 g/gram at 12 months (Figure). After month 6 and up until month 24, UPCR remained below 1 g/gram. UPCR was 1.26 g/gram with placebo at baseline and remained relatively stable over time (range 1.17–1.25 g/gram). UPCR response of ≤0.5 g/gram was achieved by 34.6% of patients receiving nefecon versus 10.4% receiving placebo. Conclusion: In the NefIgArd trial, nefecon led to a substantial and sustainable reduction in proteinuria; no appreciable reduction was seen with placebo. Mean proteinuria levels below 1 g/gram were observed with nefecon from 6 months and continued throughout the off-treatment phase to month 24. Funding: Commercial Support - Calliditas Therapeutics

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.016

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.003
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0030.002
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0010.003
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.006
GPT teacher head0.258
Teacher spread0.251 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueJournal of the American Society of Nephrology→Same topicRenal Diseases and Glomerulopathies→French-language works237,207→